AB Science S.A. (ABSCF)
| Market Cap | 82.88M -11.6% |
| Revenue (ttm) | 1.38M +9.5% |
| Net Income | -1.83M |
| EPS | -0.04 |
| Shares Out | n/a |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 192 |
| Open | 1.120 |
| Previous Close | n/a |
| Day's Range | 1.120 - 1.120 |
| 52-Week Range | 1.120 - 1.450 |
| Beta | 1.18 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | May 13, 2026 |
About AB Science
AB Science S.A., a clinical-stage company, engages in the research, design, development, and marketing of drugs to address pathologies affecting the peripheral and central nervous system, inflammatory diseases, and cancers in France. The company’s lead drug candidate is masitinib, a selective protein kinase inhibitor that targets mast cells and microglia in Phase 3 trial for the treatment of amyotrophic lateral sclerosis, progressive forms of multiple sclerosis, Alzheimer’s disease, and indolent systemic mastocytosis, as well as in Phase 2 tria... [Read more]
Financial Performance
In 2025, AB Science's revenue was 1.17 million, an increase of 9.51% compared to the previous year's 1.07 million. Losses were -1.56 million, -80.12% less than in 2024.
Financial numbers in EUR Financial StatementsNews
AB Science : Stonegate Capital Partners updates its coverage of AB Science's stock with a target price of EUR 4.25 per share
PRESS RELEASE STONEGATE CAPITAL PARTNERS UPDATES ITS COVERAGE OF AB SCIENCE'S STOCK WITH A DISCOUNTED CASH FLOW VALUATION MID-POINT OF EUR 4.25 PER SHARE Paris, June 2 nd , 2026, 6pm CET AB Science SA...
AB Science announces that its stock continues to be covered by Maxim Group, with a target price of €4.00 per share
PRESS RELEASE FOLLOWING RELEASE OF FYE2025 RESULTS AND SECURING OF CLINICAL TRIAL INSURANCE POLICY, MAXIM GROUP REITERATES ITS BUY RECOMMENDATION ON AB SCIENCE'S STOCK WITH A TARGET PRICE OF EUR 4.0 P...
AB Science reports its revenues for the year 2025 and provides an update on its activities
PRESS RELEASE AB SCIENCE PRESENTS ITS ANNUAL FINANCIAL RESULTS AS OF 31 DECEMBER 2025 AND KEY EVENTS FOR THE PERIOD Financial and corporate position Operating loss of €3.8 million as of 31 December 20...
AB Science Earnings release: H2 2025
AB Science released its H2 2025 earnings on May 13, 2026, summarizing the period's financial results.
AB Science announces the successful completion of a EUR 3.2 million private placement
PRESS RELEASE AB SCIENCE ANNOUNCES THE SUCCESSFUL COMPLETION OF A EUR 3.2 MILLION PRIVATE PLACEMENT Paris, April 29, 2026, 8am AB Science S.A. (the “Company” or “AB Science”, Euronext – FR0010557264 –...
AB Science announces a final agreement on the renegotiation of the repayment terms of its loans with all of its financial creditors
PRESS RELEASE AB SCIENCE announces a final agreement on the renegotiation of the repayment terms of its loans with all of its financial creditors AB Science has reached a final agreement with its fina...
AB Science: New publication on medrxiv demonstrating substantial survival benefits and preserved quality of life with masitinib in ALS patients
PRESS RELEASE AB SCIENCE ANNOUNCES NEW PUBLICATION ON MEDRXIV DEMONSTRATING SUBSTANTIAL SURVIVAL BENEFITS AND PRESERVED QUALITY OF LIFE WITH MASITINIB IN AMYOTROPHIC LATERAL SCLEROSIS PATIENTS Masitin...
AB Science provides an update on its clinical development program.
PRESS RELEASE AB SCIENCE PROVIDES AN UPDATE ON ITS CLINICAL PROGRAM AB SCIENCE SECURES EUR 25 MILLION CLINICAL TRIAL INSURANCE FOR ITS PHASE III TRIAL IN AMYOTROPHIC LATERAL SCLEROSIS THE POLICY COVER...
AB Science announces the identification of a plasma biomarker that indicates the activity of masitinib in treating ALS
PRESS RELEASE AB SCIENCE ANNOUNCES THE IDENTIFICATION OF A PLASMA BIOMARKER THAT INDICATES THE ACTIVITY OF MASITINIB IN TREATING AMYOTROPHIC LATERAL SCLEROSIS, AND THAT IS CAPABLE OF IDENTIFYING PATIE...
Stonegate Capital Partners Initiates Coverage on AB Science S.A. (AB)
Dallas, Texas--(Newsfile Corp. - February 10, 2026) - AB Science S.A. (ENXTPA: AB): Stonegate Capital Partners Initiates Coverage on AB Science S.A.
AB Science announced that the Food and Drug Administration (FDA) granted the status of Minor Use in Major Species (MUMS) for Masivet® in the treatment of canine mast cell tumors
PRESS RELEASE AB SCIENCE ANNOUNCES THAT THE FDA HAS GRANTED THE STATUS OF MINOR USE IN MAJOR SPECIES DESIGNATION FOR MASIVET IN THE TREATMENT OF CANINE MAST CELL TUMORS AB SCIENCE PRESENTS PERSPECTIVE...
AB Science receives Japanese patent protection for the use of masitinib in progressive forms of multiple sclerosis (MS) until 2041
PRESS RELEASE AB SCIENCE RECEIVES JAPANESE PATENT PROTECTION FOR THE USE OF MASITINIB IN PROGRESSIVE FORMS OF MULTIPLE SCLEROSIS (MS) UNTIL 2041 THIS IS THE FIRST COUNTRY DELIVERING THE MS PATENT MASI...
AB Science reports fourth consecutive case of response from Phase 1 data for the combination of AB8939 with venetoclax for the treatment of refractory or relapsed acute myeloid leukemia
AB SCIENCE REPORTS FOURTH CONSECUTIVE CASE OF RESPONSE FROM PHASE 1 DATA FOR THE COMBINATION OF AB8939 WITH VENETOCLAX FOR THE TREATMENT OF REFRACTORY OR RELAPSED ACUTE MYELOID LEUKEMIA
AB Science granted U.S. patnet for masitinib in treatment of SCD
AB Science (ABSCF) announced that the United States Patent Office has formally granted a patent for methods of treating sickle cell disease using its lead compound masitinib, based on preclinical…
AB Science patent for masitinib in the treatment of sickle cell disease formally granted in the US with a protection until 2040
PRESS RELEASE AB SCIENCE PATENT FOR MASITINIB IN THE TREATMENT OF SICKLE CELL DISEASE FORMALLY GRANTED IN THE UNITED STATES WITH A PROTECTION UNTIL 2040 THIS DECISION STRENGTHENS MASITINIB'S INTELLECT...
AB Science announces the initiation of coverage of its stock by Maxim Group with a target price of EUR 4.0 per share
PRESS RELEASE AB SCIENCE ANNOUNCES THE INITIATION OF COVERAGE OF ITS STOCK BY MAXIM GROUP WITH A TARGET PRICE OF EUR 4.0 PER SHARE Paris, December 18, 2025, 7.15pm CET AB Science SA (Euronext - FR0010...
AB Science announces a new publication on biorxiv that identifies AB8939 as a promising drug candidate for treating refractory acute myeloid leukemia and potentially other cancers
PRESS RELEASE AB SCIENCE ANNOUNCES A NEW PUBLICATION ON BIORXIV THAT IDENTIFIES AND CHARACTERIZES A NOVEL SMALL SYNTHETIC MOLECULE, AB8939, AS A PROMISING DRUG CANDIDATE FOR TREATING REFRACTORY ACUTE ...
AB Science announces new publication on Medrxiv highlighting clinical benefit with masitinib in Amyotrophic Lateral Sclerosis patients prior any complete loss of function
PRESS RELEASE AB SCIENCE ANNOUNCES NEW PUBLICATION ON MEDRXIV HIGHLIGHTING CLINICAL BENEFIT WITH MASITINIB IN AMYOTROPHIC LATERAL SCLEROSIS PATIENTS PRIOR ANY COMPLETE LOSS OF FUNCTION Significant imp...
AB Science announces the successful completion of a EUR 2.8 million private placement
PRESS RELEASE AB SCIENCE ANNOUNCES THE SUCCESSFUL COMPLETION OF A EUR 2.8 MILLION PRIVATE PLACEMENT AB SCIENCE IS FULLY FINANCED TO FINISH PHASE 1 OF AB8939 IN AML AND TO EXECUTE AN EXPANSION PHASE TO...
AB Science Transcript: Status Update
AB8939 shows promising efficacy and safety in high-risk AML patients, especially those with adverse genetic mutations, both as monotherapy and in combination with venetoclax. Expansion and registrational studies are planned, with strong expert support and a large addressable market.
AB Science Press release: Status Update
AB Science issued a press release on October 16, 2025, disclosing material business information to investors.
AB Science Quarterly report: H1 2025
AB Science has published its H1 2025 quarterly earnings report on October 10, 2025.
AB Science Earnings release: H1 2025
AB Science released its H1 2025 earnings on October 10, 2025, summarizing the period's financial results.
AB Science Earnings release: H2 2024
AB Science released its H2 2024 earnings on May 9, 2025, summarizing the period's financial results.
AB Science Transcript: Status Update
Masitinib shows strong clinical promise in ALS, Alzheimer's, and progressive MS, with new confirmatory studies approved by FDA and EMA. Robust IP protection and large addressable markets position it as a potential blockbuster, while ongoing partnerships and financing support future development.